1. Involvement of cytochrome P450 enzymes in inflammation and cancer: a review

   • Maria Carolina Stipp
   • Alexandra Acco

   Review Article 28 October 2020 Pages: 295 - 309

   

2. The use of zebrafish model in prostate cancer therapeutic development and discovery

   • Haneen Amawi
   • Alaa A. A. Aljabali
   • Amit K. Tiwari

   Review Article 03 January 2021 Pages: 311 - 325

   

3. Irinotecan-induced intestinal mucositis in mice: a histopathological study

   • Thaise Boeing
   • Marcelo Biondaro Gois
   • Luisa Mota da Silva

   Original Article 31 October 2020 Pages: 327 - 336

   

4. A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors

   • Haeseong Park
   • Kerry Williams
   • Andrea Wang-Gillam

   Original Article 06 November 2020 Pages: 337 - 347

   

5. A Phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX02 to reference CN- and EU-sourced trastuzumab in healthy subjects

   • X. Zhu
   • Y. Ding
   • Q. Zhang

   Original Article 09 November 2020 Pages: 349 - 359

   

6. Interactions between anti-EGFR therapies and cytotoxic chemotherapy in oesophageal squamous cell carcinoma: why clinical trials might have failed and how they could succeed

   • Madusha Meemanage
   • Lindsay C. Spender
   • Russell D. Petty

   Original Article Open access 09 November 2020 Pages: 361 - 377

   

7. Effects of thymidylate synthase polymorphisms on toxicities associated with high-dose methotrexate in childhood acute lymphoblastic leukemia

   • Abrar Al-Sheikh
   • Al-Motassem Yousef
   • Rand Farhad

   Original Article 10 November 2020 Pages: 379 - 385

8. A phase 1 pharmacokinetic study of oral NEPA, the fixed combination of netupitant and palonosetron, in Chinese healthy volunteers

   • Rui Chen
   • Hongyun Wang
   • Pei Hu

   Original Article 02 January 2021 Pages: 387 - 396

   

9. FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study

   • Kumiko Umemoto
   • Hideaki Takahashi
   • Masafumi Ikeda

   Original Article Open access 02 January 2021 Pages: 397 - 404

   

10. FSTL1 increases cisplatin sensitivity in epithelial ovarian cancer cells by inhibition of NF-κB pathway

    • Ya-Kun Liu
    • Ya-Jing Jia
    • Jing Ma

    Original Article 03 January 2021 Pages: 405 - 414

    

11. Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer

    • Shuang Liu
    • Shoujing Zhao
    • Guan Wang

    Original Article 03 January 2021 Pages: 415 - 423

    

12. Pingyangmycin enhances the antitumor efficacy of anti-PD-1 therapy associated with tumor-infiltrating CD8⁺ T cell augmentation

    • Chuan-Kun Shan
    • Yi-Bo Du
    • Yong-Su Zhen

    Original Article 03 January 2021 Pages: 425 - 436

    

13. BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series

    • Sabeeh-ur-Rehman Butt
    • Alberto Mejias
    • Hendrik-Tobias Arkenau

    Short Communication 03 February 2021 Pages: 437 - 441

    

14. Acknowledgement of reviewers 2020

    Acknowledgement 10 February 2021 Pages: 443 - 446